Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors
about
Necrotizing enterocolitis: new insights into pathogenesis and mechanismsModeling-Enabled Characterization of Novel NLRX1 LigandsAnimal models of gastrointestinal and liver diseases. Animal models of necrotizing enterocolitis: pathophysiology, translational relevance, and challenges.Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets: evidence in mice for a role of TLR9.Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women.Evidence-based feeding strategies before and after the development of necrotizing enterocolitis.The gut microbiome, kidney disease, and targeted interventions.Intestinal Epithelial TLR-4 Activation Is Required for the Development of Acute Lung Injury after Trauma/Hemorrhagic Shock via the Release of HMGB1 from the GutFactors influencing gastrointestinal tract and microbiota immune interaction in preterm infants.Breast milk protects against the development of necrotizing enterocolitis through inhibition of Toll-like receptor 4 in the intestinal epithelium via activation of the epidermal growth factor receptorThe human milk oligosaccharide 2'-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestineToll-like receptor 4-mediated lymphocyte influx induces neonatal necrotizing enterocolitis.The immunological landscape in necrotising enterocolitisToll-like receptor regulation of intestinal development and inflammation in the pathogenesis of necrotizing enterocolitis.TLR4 signalling in osteoarthritis--finding targets for candidate DMOADs.LPS Induces Hyper-Permeability of Intestinal Epithelial Cells.Resident Macrophages in Muscle Contribute to Development of Hyperalgesia in a Mouse Model of Noninflammatory Muscle Pain.FLLL32, a curcumin analog, ameliorates intestinal injury in necrotizing enterocolitis.Current Research on the Epidemiology, Pathogenesis, and Management of Necrotizing Enterocolitis.Leucine-rich repeat 2 of human Toll-like receptor 4 contains the binding site for inhibitory monoclonal antibodies.E5564 inhibits immunosuppressive cytokine IL-10 induction promoted by HIV-1 Tat proteinSynthesis of anti-inflammatory α-and β-linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4).Pulmonary Epithelial TLR4 Activation Leads to Lung Injury in Neonatal Necrotizing Enterocolitis.Pore-forming toxin-mediated ion dysregulation leads to death receptor-independent necroptosis of lung epithelial cells during bacterial pneumonia.Tissue engineering for the treatment of short bowel syndrome in children.An inhibitory epitope of human Toll-like receptor 4 resides on leucine-rich repeat 13 and is recognized by a monoclonal antibody.Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases.Immunothrombotic Activity of Damage-Associated Molecular Patterns and Extracellular Vesicles in Secondary Organ Failure Induced by Trauma and Sterile Insults.Regional microglia are transcriptionally distinct but similarly exacerbate neurodegeneration in a culture model of Parkinson's disease.
P2860
Q28079458-E7F81372-C945-431D-933C-F5E31A0FDDE2Q28551839-F6B5E44F-9273-4CCC-8F4C-AB8C62B9CD4AQ33701575-73411882-E92A-4E41-8BAB-39DAE7D5F40CQ33701606-4FA98190-F004-4A14-8AC9-A681D7AD6F71Q33744915-56CC908D-977A-492C-A9C9-B101FADBB754Q33962474-92367B79-3A55-4633-8E25-FD6E54B82C43Q35042986-3661936E-D10B-410A-A1D0-4B4DCA966E57Q35562915-E68D5C4B-7993-4109-BF0F-6FFCCE3A9192Q35575131-6344C0DF-12FC-40B1-94B9-926CC511F4D2Q35967645-08C8584E-C049-4EBA-AEFA-B5A76156B162Q36127329-BE7B9B11-B7BE-4CAA-A312-58585916752BQ36515093-12E1B92C-B9CE-4BB7-A7B1-6ABA856CD939Q37210802-373C3369-92BC-4057-917C-F649586ADE20Q38173600-20A1211D-6F61-472C-A3F5-991B780D5C3AQ38289811-F03FE6CE-0233-450B-A46E-F24ABE4D4A7FQ38735352-4E30904C-9DE7-4993-8FF3-5C198C757E37Q39632740-8D70D48D-70A8-433C-BD53-6C49BF26300DQ40156995-7EBA7968-B2B9-412B-8A17-825CEACB5B53Q40188129-429A74C2-13F0-4B22-B365-6E7F921CDB8CQ40280609-728D3222-1F4D-44FB-962B-89044B16C1A6Q41620362-BC9FD492-4147-46DE-ABA8-AAE29C6D0BA8Q41882467-F82AF91E-7AC2-4133-8B4C-7B8A7A3D4107Q42166575-6A340EFF-2123-4C67-9B7D-5BD195BE2D34Q46388233-ABA39705-B821-49EE-864C-5DC3DAD2C803Q47646913-BB1DE89F-8D33-48FA-8FFF-DD251AB6ABACQ48031043-9DA27D1A-C801-4060-A926-DAE8068BD4D6Q48129259-7AD300BF-0F63-4619-8EA8-14B08A23A9E5Q50324081-430D35CE-D942-45DC-B447-11192E39929BQ54960390-0879528E-FC75-4131-9948-0C17F9221CCC
P2860
Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@ast
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@en
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@nl
type
label
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@ast
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@en
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@nl
prefLabel
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@ast
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@en
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@nl
P2093
P2860
P1433
P1476
Discovery and validation of a ...... e receptor 4 (TLR4) inhibitors
@en
P2093
Amin Afrazi
Benjamin Eyer
Chhinder P Sodhi
Christopher J Guerriero
Congrong Ma
David J Hackam
Hongpeng Jia
Jeffrey L Brodsky
John Ozolek
Maria Branca
P2860
P304
P356
10.1371/JOURNAL.PONE.0065779
P407
P577
2013-01-01T00:00:00Z